Up to 6 FP002 dose levels (0.3, 1.0, 3.0, 10, 20, 30 mg/kg administered intravenously may be evaluated. Subjects will receive weekly infusions of FP002 until disease progression, unacceptable toxicity, consent withdrawal, physician decision, or start of subsequent anticancer therapy, whichever occurs first.

FP002 Injection

Arron Wang

Vincent Huo

Wang Sheng

Wang Sheng, M.M.

Yuping Sun, MD

Yuping Kong, MD

Linlin Wang, MD

Zhen Wang

The goal of this phase 1 study is to assess the safety, and tolerability of FP002 to determine the dose recommended for dose expansion in subjects with advanced solid tumor.

This study is a phase 1 study of FP002 as monotherapy in patients with advanced solid tumor. The study will evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic profile, immunogenicity, and preliminary anti-tumor activity of FP002 in patients with advanced solid tumors.

A Study to Investigate FP002 in Subjects With Advanced Malignancies

A Phase 1 Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics Activity of FP002 in Subjects With Advanced Malignancies

Guangdong Fapon Biopharma Inc.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
A Study to Investigate FP002 in Subjects With Advanced Malignancies	NCT05982080	Advanced Solid ...	FP002 Injection	18 Years -	Guangdong Fapon Biopharma Inc.
A Study to Investigate FP002 in Subjects With Advanced Malignancies	NCT05982080	Advanced Solid ...	FP002 Injection	18 Years -	Guangdong Fapon Biopharma Inc.
A Study to Investigate FP002 in Subjects With Advanced Malignancies	NCT05982080	Advanced Solid ...	FP002 Injection	18 Years -	Guangdong Fapon Biopharma Inc.

Spots Global Cancer Trial Database for fp002 injection